Head to Head Survey: Omnicell (NASDAQ:OMCL) & Coloplast A/S (OTCMKTS:CLPBY)

Coloplast A/S (OTCMKTS:CLPBY) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Coloplast A/S and Omnicell”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coloplast A/S	$4.50 billion	3.67	$478.04 million	$0.21	34.86
Omnicell	$1.18 billion	1.39	$2.05 million	$0.96	37.40

Coloplast A/S has higher revenue and earnings than Omnicell. Coloplast A/S is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Coloplast A/S has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Insider & Institutional Ownership

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Coloplast A/S and Omnicell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coloplast A/S	10.57%	42.25%	11.87%
Omnicell	3.59%	5.69%	3.61%

Analyst Ratings

This is a summary of current recommendations for Coloplast A/S and Omnicell, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coloplast A/S	1	1	0	2	2.75
Omnicell	0	1	7	1	3.00

Omnicell has a consensus target price of $57.86, suggesting a potential upside of 61.16%. Given Omnicell’s stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Coloplast A/S.

Summary

Coloplast A/S beats Omnicell on 8 of the 15 factors compared between the two stocks.

About Coloplast A/S

Coloplast A/S is a Danish medical device company that develops and markets products and services for people with intimate health care needs. Its main business areas include ostomy care, continence care, wound and skin care, and urology care. Its products include ostomy bags and accessories, catheters and other continence products, wound dressings, and devices used in urological procedures. Coloplast also provides voice and respiratory care products, including solutions for people who have had a laryngectomy.

About Omnicell

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.